Research Article
Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
Table 2
Sensitivity and uptake of 68Ga-DOTATATE and 18F-FDG PET/CT for different primary sites and grades.
| | | Sensitivity (%) | (mean ± SD) | | 68Ga-DOTATATE | 18F-FDG PET/CT | 68Ga-DOTATATE | 18F-FDG PET/CT |
| | Primary lesion | | | | | | Gastrointestinal tract | 55.8% | 74.4% | 16.75 ± 2.62 | 7.56 ± 0.87 | | Pancreas | 85.2% | 66.7% | 29.87 ± 4.77 | 6.51 ± 0.78 | | WD NET | 80.4% | 58.8% | 28.87 ± 3.52 | 4.51 ± 0.45 | | Gastrointestinal NET | 75.0% | 54.2% | 22.68 ± 2.77 | 3.71 ± 0.45 | | Pancreatic NET | 89.5% | 52.6% | 31.19 ± 4.25 | 5.13 ± 0.93 | | PD NEC | 37.5% | 100.0% | 10.86 ± 1.78 | 11.46 ± 0.75 | | Gastrointestinal NEC | 31.6% | 100.0% | 9.26 ± 1.25 | 12.44 ± 1.11 | | Pancreatic NEC | 75.0% | 100.0% | 18.23 ± 5.93 | 10.23 ± 0.67 |
|
|
WD, well-differentiated; PD, poorly differentiated; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma.
|
